NASDAQ:ALP Portage Biotech Q2 2026 Earnings Report $5.58 -0.03 (-0.53%) As of 09/25/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Portage Biotech EPS ResultsActual EPS-$206.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APortage Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APortage Biotech Announcement DetailsQuarterQ2 2026Date1/21/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Portage Biotech Earnings HeadlinesAlpha Compute Regains Full Compliance with Nasdaq Listing RulesSeptember 25 at 8:00 AM | globenewswire.comPortage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Purchases 10,000 SharesSeptember 24 at 6:09 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 27 at 1:00 AM | The Oxford Club (Ad)Alpha Compute Signs Binding Contract to Acquire Assets of Operating Oil and Gas Business in PennsylvaniaSeptember 22, 2026 | globenewswire.comPortage Biotech (NASDAQ:ALP) Insider Buys $17,273.25 in StockSeptember 20, 2026 | americanbankingnews.comCore Scientific (NASDAQ:CORZ) versus Portage Biotech (NASDAQ:ALP) Financial SurveySeptember 18, 2026 | americanbankingnews.comSee More Portage Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email. Email Address About Portage BiotechPortage Biotech (NASDAQ:ALP) is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses. The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response. As a development-stage biotechnology company, Portage’s products remain subject to clinical testing and regulatory review and are not established commercial therapies. Portage Biotech is incorporated in the British Virgin Islands and has pursued a geographically distributed research and development strategy through collaborations and affiliated biotechnology businesses. Publicly available company information identifies the business as Portage Biotech, Inc.; however, its commonly reported Nasdaq symbol has been PRTG rather than ALP. Leadership and pipeline details may change as the company advances its programs and updates its corporate structure.View Portage Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
